This week, I want to talk about something that’s been absolutely dominating the pharmaceutical world: GLP-1 drugs. You’ve heard of Ozempic, Wegovy, Mounjaro, Zepbound. The weight-loss revolution that’s turned into one of the biggest gold rushes in pharma history.
But here’s what most people miss: While everyone’s been watching Eli Lilly and Novo Nordisk fight over who gets to be the first $1 trillion pharma company, there’s a whole ecosystem of smaller biotechs racing to capture their slice of what analysts are calling a $470 billion market by 2030.
Today, I’m breaking down Eli Lilly’s incredible run—the numbers are genuinely mind-blowing—and then showing you two companies that could potentially ride the same wave. These aren’t household names.
Most retail investors have never heard of them. But they’re backed by solid science, real clinical data, and the kind of catalysts that can turn a $3 billion biotech into a $20 billion acquisition target overnight.
Let’s dive in.
Part 1: The Eli Lilly Case Study — When A Drug Becomes A Cultural Phenomenon
The Numbers That Break Your Brain
Let me start with the headline figures, because they’re almost comical:
Q3 2025 Earnings:
Mounjaro revenue: $6.52 billion (up 109% YoY)
Zepbound revenue: $3.59 billion (up 184% YoY)
Combined: Nearly $10 billion in a single quarter from just two drugs
Think about that. Ten billion dollars. In 90 days. From two medications that are essentially the same compound (tirzepatide) with different labels.
For context, most biotech companies would kill to make $10 billion in total revenue for an entire year. Eli Lilly is doing it per quarter with a drug that’s been on the market for less than three years.
Full Year 2025 Guidance: The company now expects revenue between $63-63.5 billion, up from previous guidance of $60-62 billion. That’s a 40% revenue increase compared to 2024’s $45 billion.
And here’s the kicker: Mounjaro and Zepbound now represent 48% of Eli Lilly’s total revenue. Nearly half of a $900+ billion company’s sales comes from one molecule.
The Market Share Dominance
The story gets even better. Eli Lilly now controls almost 6 out of 10 prescriptions in the injectable GLP-1 market. That’s not just winning—that’s obliterating the competition.
For the fifth consecutive quarter, Eli Lilly has been gaining market share. Novo Nordisk, the company that basically invented this category with Ozempic, is getting pushed aside. Novo’s stock is down 37% year-to-date. Eli Lilly’s is essentially flat, which in a market where expectations were sky-high, is actually impressive.
Why is Eli Lilly winning?
Efficacy: Clinical trials suggest tirzepatide is simply more effective than semaglutide for weight loss
Direct-to-consumer strategy: LillyDirect sells vials at $500/month, undercutting everyone
Supply chain: They’ve invested $50+ billion in manufacturing capacity
Global expansion: Launching in China, Brazil, India in 2025 opened massive new markets
The Next Chapter: The Oral Pill That Changes Everything
Here’s where it gets really interesting.
Injectable drugs are great, but everyone prefers a pill. Eli Lilly’s experimental oral GLP-1, orforglipron, is expected to receive FDA approval by March 2026.
If that happens—and early Phase 3 data looks promising—it could be another multi-billion-dollar blockbuster. Most patients will choose a daily pill over a weekly injection. It’s just human nature.
Industry analysts project that by 2030, Eli Lilly will be the world’s largest pharmaceutical company by revenue, hitting $113 billion in prescription drug sales. For perspective, that’s nearly triple their 2024 revenue of $41 billion.
Part 2: The Valuation Reality Check — Is Eli Lilly Already Too Expensive?
Now, before you rush to buy Eli Lilly stock, let’s pump the brakes.
The Problem: Everything Is Already Priced In
Current valuation metrics:
Trading at: ~$1,018 per share
Wall Street consensus target: $973.85
Forward P/E ratio: 31x (industry average is 15x)
You’re basically paying a massive premium for a stock that already reflects its dominance. There’s very little room for error.
The Risks That Could Derail The Story
1. Competition Is Coming (And It’s Serious)
The obesity market is so lucrative that every major pharma company wants in:
Novo Nordisk is cutting 9,000 jobs to reallocate resources and compete harder
Roche bought Carmot Therapeutics for $2.7 billion to get GLP-1 assets
Merck, AbbVie, Amgen, Pfizer—all racing to launch competitors
2. The Oral Pill Might Have Tolerability Issues
In Phase 3 trials for diabetes, orforglipron showed an 8% discontinuation rate due to side effects. That’s not catastrophic, but if patients can’t tolerate it, the blockbuster potential evaporates.
3. Compounded Drugs Are Cannibalizing Sales
Off-brand “compounded” versions of GLP-1 drugs are eating into market share. Regulatory changes in May 2025 might help, but it’s a real threat.
4. Extreme Dependence on One Drug
Remember: 48% of revenue comes from tirzepatide. If anything goes wrong—patent challenges, safety issues, a competitor with better efficacy—Eli Lilly’s stock would crater.
The Bottom Line on Eli Lilly
It’s an incredible company. World-class management. Best-in-class drug. But at $1,000+ per share with a 31x P/E, the opportunity for massive gains has already happened.
What we want as investors looking for alpha is companies where the story hasn’t been fully written yet—where you’re buying at 10x P/E before the market realizes what’s happening, not after it’s already tripled in value.
So let’s talk about two companies that fit that profile.